Clients News • MC Services corporate website
5522
page-template-default,page,page-id-5522,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.4.2,vc_responsive

CLIENT NEWS

 

 

  • Marinomed Biotech AG Leads BCG’s Gender Diversity Index Austria 2020
    www.marinomed.com
  • InflaRx Announces Pricing of $75 Million Public Offering of Common Shares and One-Year Warrants
    www.inflarx.de
  • DEBx Medical Receives CE Mark and ISO 13485 Certification for Debrichem® for Chemical Debridement
    www.debx-medical.com
  • Marinomed Biotech AG announces positive clinical data for Carragelose lozenges against respiratory viruses including SARS-CoV-2
    www.marinomed.com
  • Relief Reports that NeuroRx Announced that RLF-100™ (Aviptadil) has Successfully Demonstrated Ten-Day Accelerated Recovery from Respiratory Failure among Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28 Day Interim Endpoint
    www.relieftherapeutics.com
  • RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.
    www.redhillbio.com
  • XPhyto builds commercial team to launch 25-minute COVID-19 RT-PCR test
    www.xphyto.com
  • Marinomed Biotech AG shares positive clinical trial results for iota-carrageenan nasal spray in the prevention of COVID-19
    www.marinomed.com
  • RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204
    www.redhillbio.com
  • Marinomed Biotech AG publishes new supporting data on the in vitro efficacy of Carragelose® against SARS-CoV-2
    www.marinomed.com